February 29th is Rare Disease Day

February 29th is Rare Disease Day. In the United States alone, according to the National Organization for Rare Diseases (NORD), at least 25-30 million individuals fight invisible battles against rare diseases. That’s right, millions. But what defines “rare”? By NORD’s definition, it affects less than 200,000 people in the US, although different countries may have varying thresholds. Consider conditions like Neurofibromatosis, impacting 1 in every 2,000 births a stark reminder that rare doesn’t mean isolated.

Joining the Conversation

Rare Disease Day isn’t just about statistics; it’s about action. Here’s how you can make a difference:

  • Share your story. If you’re comfortable, use your voice to raise awareness. Even anonymously, your experience can help others feel less alone.
  • Become an information hub. Share details about local and national rare disease advocacy organizations.
  • Get creative. Organize a DIY fundraising event and donate the proceeds to your chosen non-profit. Every bit counts!
  • Connect with community. Find local Rare Disease Day events near you. Sharing the journey strengthens everyone.

Beyond February 29th

Advocacy doesn’t have to wait for the rarest day. Let’s continue the conversation and support those living with rare diseases throughout the year. Together, we can shine a light on their challenges and champion their needs.

Together, let’s make every day a Rare Disease Day of awareness, empathy, and action.


Recent Posts

  • Your Support Helps Connect Families to NF Clinical Trials

    Behind every clinical trial is a team that keeps it running day to day. For 45 years, NF Midwest has supported research into the many complications of NF1, NF2-related schwannomatosis, and other forms of schwannomatosis. Today, that investment is paying off close to home. NF clinical trials are happening right here in the Midwest, and... Read More
  • Barriers to Healthcare Access and Psychosocial Experiences in Adults with Neurofibromatosis Type 1

    Offered by: University of Colorado AnschutzConducted by: Katelyn Glowinski, genetic counseling student, master’s program This research study is designed to gain a better understanding of healthcare barriers faced by adults with Neurofibromatosis Type 1 (NF1), as well as evaluate any associations between these barriers and your self-reported neuropsychiatric or mental health status. If you join... Read More

Responses

Respond

Your email address will not be published. Required fields are marked *